Argent Biopharma’s CannEpil to Target $3bn Veterinary Pain Market, Weeks After Debt-Relief Deal

Argent Biopharma’s (RGT) flagship CannEpil cannabis drug is set to pivot into the veterinary market, just weeks after it signed away the commercial rights in exchange for debt relief.  Last month, Business of Cannabis reported that Argent (previously MGC Pharmaceuticals), had signed a US$5.5m debt-for-equity licensing deal with Splash Beverage Group, handing it the responsibility…

Access Denied

Access Denied You don’t have permission to access “http://www.firstpost.com/business/yen-intervention-may-offer-brief-relief-but-debt-risks-could-push-usd-jpy-to-180-14036430.html” on this server. Reference #18.2dc7ce17.1786043736.135fd9f2 https://errors.edgesuite.net/18.2dc7ce17.1786043736.135fd9f2 Read the original article here